CVD Risk and Health in Postmenopausal Phytoestrogen Users
Primary Purpose
Bone Diseases, Cardiovascular Diseases, Coronary Disease
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
dietary supplements
genistein
diet, soy proteins
Sponsored by
About this trial
This is an interventional prevention trial for Bone Diseases
Eligibility Criteria
Postmenopausal women, ages 45 to 74.
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00000613
First Posted
October 27, 1999
Last Updated
February 26, 2016
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00000613
Brief Title
CVD Risk and Health in Postmenopausal Phytoestrogen Users
Study Type
Interventional
2. Study Status
Record Verification Date
December 2005
Overall Recruitment Status
Completed
Study Start Date
April 1997 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
5. Study Description
Brief Summary
To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.
Detailed Description
BACKGROUND:
Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen.
DESIGN NARRATIVE:
Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo groups are performed before and after adjustment and stratification for potentially confounding covariates.
The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone Diseases, Cardiovascular Diseases, Coronary Disease, Depression, Heart Diseases, Myocardial Ischemia, Osteoporosis, Postmenopause
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Behavioral
Intervention Name(s)
dietary supplements
Intervention Type
Drug
Intervention Name(s)
genistein
Intervention Type
Behavioral
Intervention Name(s)
diet, soy proteins
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Postmenopausal women, ages 45 to 74.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donna Kritz-Silverstein
Organizational Affiliation
University of California, San Diego
12. IPD Sharing Statement
Citations:
PubMed Identifier
11285326
Citation
Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. 2001 Apr;131(4):1202-6. doi: 10.1093/jn/131.4.1202.
Results Reference
background
PubMed Identifier
11860727
Citation
Kritz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. J Womens Health Gend Based Med. 2002 Jan-Feb;11(1):69-78. doi: 10.1089/152460902753473480.
Results Reference
background
PubMed Identifier
14501604
Citation
Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake and body composition in postmenopausal women. Menopause. 2003 Sep-Oct;10(5):427-32. doi: 10.1097/01.GME.0000058866.35869.B4.
Results Reference
background
Learn more about this trial
CVD Risk and Health in Postmenopausal Phytoestrogen Users
We'll reach out to this number within 24 hrs